Claims
- 1. A compound having a formula
- 2. The compound of claim 1 represented by the formula
- 3. The compound of claim 1 wherein R0 is hydrogen.
- 4. The compound of claim 1 wherein R1 is selected from the group consisting of hydrogen, C1-4alkyl, haloC1-4alkyl, optionally substituted benzyl, C3-6cycloalkylmethyl, pyridylC1-3alkyl, and furylC1-3alkyl.
- 5. The compound of claim 1 wherein R3 is hydrogen.
- 6. The compound of claim 1 wherein R1 and R3 together represent a 3- or 4-membered alkyl chain component.
- 7. The compound of claim 1 wherein R2 is selected from the group consisting of hydrogen, C1-6alkyl, arylC1-3alkyl, C1-3alkenylaryl, C3-6cyclo-alkyl, Het, C3-6cycloalkenyl, C1-4alkyleneHet, C1-4alkyleneQRa, C2-4alkenyleneQRa, C1-4alkyleneQC1-4-alkyleneQRa,
- 8. The compound of claim 1 wherein R2 is selected from the group consisting of
- 9. The compound of claim 8 wherein Ra is selected from the group consisting of hydrogen, C1-6alkyl, and benzyl.
- 10. A compound selected from the group consisting of
- 11. A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.
- 12. A method of treating a male or female animal for a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising administering to said animal an effective amount of a pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.
- 13. The method of claim 12 wherein the condition is male erectile dysfunction.
- 14. The method of claim 13 wherein the treatment is an oral treatment.
- 15. The method of claim 12 wherein the condition is female arousal disorder.
- 16. The method of claim 15 wherein the treatment is an oral treatment.
- 17. The method of claim 12 wherein the condition is selected from the group consisting of stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, acute respiratory distress syndrome, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, a peripheral vascular disease, a vascular disorder, thrombocythemia, an inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, a gut motility disorder, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, post-bypass surgery graft stenosis, osteoporosis, preterm labor, benign prostatic hypertrophy, and irritable bowel syndrome.
- 18. A method of treating a condition where inhibition of a cGMP-specific PDE is of therapeutic benefit, in a human or a nonhuman animal body, comprising administering to said body a therapeutically effective amount of a compound of claim 1.
- 19. A method for the curative or prophylactic treatment of male erectile dysfunction or female arousal disorder, comprising administration of an effective dose of a compound of claim 1, and pharmaceutically acceptable salts and solvates thereof, to an animal.
- 20. Use of a compound of claim 1 for the manufacture of a medicament for the curative or prophylatic treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims benefit of provisional U.S. patent application 60/237,477, filed Oct. 2, 2000.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/28972 |
9/17/2001 |
WO |
|